Check out this photo illustration of the Madrigal Pharmaceuticals logo on a smartphone screen. The Food and Drug Administration has just given the green light to the first-ever treatment for a common and potentially deadly form of liver disease that affects millions worldwide. This is a major win for Madrigal Pharmaceuticals, as several larger companies have failed in this area. The approval has caused Madrigal shares to soar more than 20% in extended trading. Other companies like Novo Nordisk and Eli Lilly are also working on treatments for the same liver disease, but Madrigal’s drug, Rezdiffra, is the first to receive FDA approval for patients with moderate-to-advanced liver scarring. The treatment must be used with diet and exercise. Exciting news for the pharmaceutical industry!
2024-03-14 18:08:37
Source from www.cnbc.com
